Twelve of the 65 participating companies were selected to pitch a group of over 100 chief medical information officers, chief information officers and chief medical officers from U.S. hospitals, along with venture capitalists and industry representatives.
Spin-off company based on founder Razieh Niazi’s research at York University
TORONTO, Dec. 6, 2012 — Kaypok Inc., a start-up company whose technology delivers insight into unstructured big data, today announced that it has selected Zync as its agency of record to create and launch Kaypok’s brand globally.
Kaypok Inc., which was spun off from York University research with support and funding from MaRS Innovation, filters, categorizes, identifies meaning and measures the root cause and emotions buried within unstructured text to understand what people are saying and feeling. Kaypok Inc. launched nationally at the iStrategy Digital Marketing Conference in Toronto on December 4, 2012.
MaRS Innovation joins the MaRS Discovery District in congratulating Dr. Ilse Treurnicht on receiving the prestigious 2012 Canada’s Most Powerful Women: Top 100™ Award. The full release about Dr. Treurnicht's…
Company to Present on Social Media Behavior and Deep Root Cause Analysis at iStrategy Toronto December 4
TORONTO (December 4, 2012) — Companies are drowning in a sea of big, unstructured, noisy data. Whether it’s social media chatter, email or survey results, how do you filter the noise and take action?
Kaypok Inc., a company spun off from York University research with support and funding from MaRS Innovation, uses a contextual natural language process to automatically interpret the meaning of raw data — without analysts, advance preparation, special databases or lag time.
VitalHub Chart has been named to Apple’s list of top 80 apps for doctors, nurses, patients and healthcare professionals in the “EMR and patient monitoring” category.
Here’s a description of the app, which is made by Toronto-based VitalHub Corp., from the Apple list curators:
“VitalHub Chart puts patient data at your fingertips. You can access the information you need any time, anywhere there is WiFi or cellular service. No more waiting for a free desktop, hunting for a workstation on wheels, or carrying printouts on rounds.”
The event, hosted by the Centre for International Governance Innovation (CIGI), will include a live stream of talks from the second annual TedxWomen conference in Washington, D.C., along with talks by local speakers, including Monier-Williams, for the Waterloo audience.
Being named to the MIT Technology Review's 35 Inventors Under 35 list is a prestigious honour, but one of its best perks is the subsequent invitation to attend the Emerging…
OtoSim Inc., a MaRS Innovation spin-of company, was featured along with MaRS Innovation in the Autumn 2012 edition of Health Research & Innovation magazine. The article by Tim Wilson is…
GEN Magazine (Genetic Engineering and Biotechnology News) featured the microfluidics research of Dr. Aaron Wheeler on November 15, 2012.
Wheeler, Canada Research Chair of Bioanalytical Chemistry and an associate professor at the University of Toronto, has made an invention disclosure to MaRS Innovation; Kapplex is the start-up company created to commercialize his research.
TORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.
“Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, director, OICR’s Medicinal Chemistry Platform. “OICR is proud to invest in a technology that has such potential to one day improve quality of life for cancer patients.”
Cellax, invented by Dr. Shyh-Dar Li and his research team in OICR’s Medicinal Chemistry Platform group, is a drug-polymer conjugate based on Dr. Li’s proprietary NanoCMC™ technology. These polymers self-assemble into defined nanoparticles and, when injected, selectively accumulate in tumours. Because of this property, the drug is released where it is most needed, increasing therapeutic benefits and reducing the side effects associated with conventional chemotherapy.
Bedside Clinical Systems (BCS) participated in Philadelphia’s 2012 Canada-U.S. eHealth Summit on November 28.
TORONTO, Dec. 6, 2012 — 
